Regeneron Pharmaceuticals (REGN) News Today

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is being supported by a major expansion of its immunology partnership with Sanofi, encouraging clinical data, and bullish analyst actions. However, investors may remain cautious about early-stage oncology results and the execution risk associated with developing several new antibody candidates.

• Positive Sentiment: Sanofi alliance expanded, with substantial upfront and milestone potential. Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in additional milestones for four next-generation, long-acting antibodies targeting type 2 inflammation. The companies will share development and commercialization costs and future profits, strengthening Regeneron’s immunology pipeline beyond Dupixent. Sanofi pays Regeneron up to $8B to expand immunology alliance
• Positive Sentiment: Weight-loss combination data address a key GLP-1 concern. In the Phase 2 COURAGE trial, trevogrumab preserved approximately 70% of the muscle lost by patients receiving semaglutide alone in an MRI substudy. The result could give Regeneron a differentiated position in the obesity market, although additional development and regulatory work remain. Phase 2 COURAGE Trial results
• Positive Sentiment: Analysts became more constructive. Jefferies raised its price target to $930 and maintained a buy rating, while Argus upgraded REGN to buy with an $850 target. These actions suggest improved confidence in the company’s pipeline and longer-term growth prospects.
• Neutral Sentiment: Ubamatamab showed promising but early oncology results. The therapy produced a 73% objective response rate and 11-month median progression-free survival in 11 heavily pretreated patients with low-grade serous ovarian cancer. The small, early-stage dataset is encouraging but requires confirmation in larger studies. Ubamatamab ovarian cancer study
• Negative Sentiment: Investors appeared underwhelmed by the ovarian cancer data. Despite the high response rate, reports indicated that REGN came under pressure after the early-stage readout, likely reflecting concerns about the limited patient sample, durability, and the distance to possible approval.